What is HC Wainwright’s Estimate for Kamada FY2025 Earnings?

Kamada Ltd. (NASDAQ:KMDA) – Stock analysts at HC Wainwright decreased their FY2025 earnings per share estimates for shares of Kamada in a research note issued on Thursday, March 6th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will earn $0.28 per share for the year, down from their prior estimate of $0.31. HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Kamada’s current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Kamada’s FY2026 earnings at $0.38 EPS, FY2027 earnings at $0.45 EPS and FY2028 earnings at $0.54 EPS.

Kamada Trading Up 0.6 %

KMDA opened at $7.12 on Monday. Kamada has a 1-year low of $4.74 and a 1-year high of $9.15. The stock’s fifty day simple moving average is $7.18 and its 200 day simple moving average is $6.19. The stock has a market cap of $409.26 million, a PE ratio of 25.43, a price-to-earnings-growth ratio of 0.97 and a beta of 0.97.

Kamada Announces Dividend

The firm also recently declared a dividend, which will be paid on Monday, April 7th. Investors of record on Monday, March 17th will be paid a $0.20 dividend. The ex-dividend date of this dividend is Monday, March 17th.

Institutional Investors Weigh In On Kamada

A number of large investors have recently added to or reduced their stakes in KMDA. Plato Investment Management Ltd bought a new stake in Kamada in the 3rd quarter valued at $117,000. Public Employees Retirement System of Ohio bought a new stake in Kamada in the 3rd quarter valued at $77,000. JPMorgan Chase & Co. bought a new stake in Kamada in the 4th quarter valued at $67,000. NewEdge Advisors LLC grew its holdings in Kamada by 54.2% in the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after buying an additional 8,260 shares in the last quarter. Finally, Aristides Capital LLC grew its holdings in Kamada by 12.1% in the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock valued at $387,000 after buying an additional 6,850 shares in the last quarter. Institutional investors own 20.38% of the company’s stock.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.